-

Mg OSTEOINJECT from Bone Solutions Receives 510(k) Clearance for Expanded Indications

COLLEYVILLE, Texas--(BUSINESS WIRE)--Bone Solutions Inc. (BSI), an orthobiologics technology company located in Colleyville, Texas, announced today that it has received FDA 510(k) clearance for expanded indications for its Mg OSTEOINJECT. Mg OSTEOINJECT is the first drillable, adhesive, and injectable bone void filler in the U.S. to incorporate magnesium, a critical component for bone health and development.

The expanded indication includes use of the material as an adjunct to hardware fixation by supporting the bone fragments during the surgical procedure. Magnesium-based Mg OSTEOINJECT showed nearly 30% greater anchoring strength compared to traditional PMMA.1

Mg OSTEOINJECT also provides a minimally invasive treatment option for insufficiency and micro fractures via percutaneous skeletal fixation. The adhesive properties and unique resorption profile of Mg OSTEOINJECT provide stability, increasing cell proliferation and advancing mineralization that results in enhanced bone regeneration in a broad range of orthopedic applications.

Mg OSTEOINJECT is currently being distributed to facilities and surgical centers nationwide for immediate clinical use.

About Bone Solutions Inc.

Bone Solutions Inc. (‘BSI’) is a specialized medical device company dedicated to improving clinical outcomes through biologically safe, fully resorbable magnesium-based orthopedic implant solutions, with a focus on addressing complex procedures and cost reduction. The company is developing various new orthopedic technologies within its FDA-cleared magnesium-based platform.

1Bertone, AL; DeMaria, MG; Johnson, AL; Weisbrode, SE; Kowaleski, MP, Comparative Orthopaedic Research and Bone Laboratories, College of Veterinary Medicine, The Ohio State University, Columbus, OH, 52nd Annual Meeting of the Orthopaedic Research Society, Paper No: 0876 "Degradable Magnesium Based Cement Adheres Stainless Steel Screws Into Bone."

“Mg OSTEOINJECT” is a registered trademark of Bone Solutions, Inc.

Contacts

Media Contact: Paul Williams, MediaLine Communications, 310-569-0023
paul@medialinecommunications.com

Company Contact: Drew Diaz, Bone Solutions Inc., 817-809-8850
diaz@bonesolutions.net

Bone Solutions Inc.


Release Versions

Contacts

Media Contact: Paul Williams, MediaLine Communications, 310-569-0023
paul@medialinecommunications.com

Company Contact: Drew Diaz, Bone Solutions Inc., 817-809-8850
diaz@bonesolutions.net

Social Media Profiles
More News From Bone Solutions Inc.

Bone Solutions’ Mg OSTEOCRETE and Mg OSTEOINJECT Receive FDA Clearance for Pediatric Use in Patients Aged Six and Older

COLLEYVILLE, Texas--(BUSINESS WIRE)--Bone Solutions Inc., a Colleyville-based orthobiologics company specializing in magnesium-based technologies, announced that the U.S. Food and Drug Administration (FDA) has granted pediatric clearance for its Mg OSTEOCRETE and Mg OSTEOINJECT products. The clearance allows use of the technologies in pediatric patients aged six years and older. This expanded indication highlights the adaptability of Bone Solutions’ proprietary magnesium-based platform, particu...

Bone Solutions Announces Five New Patents Awarded in FY25, Further Enhancing Its Core Mg OSTEOCRETE Technology

COLLEYVILLE, Texas--(BUSINESS WIRE)--Bone Solutions Inc., an orthobiologics technology company located in Colleyville, Texas, announced today its fifth patent awarded this year from the U.S. Patent and Trademark Office (USPTO) related to Mg OSTEOCRETE, a portfolio of patents that includes current and future configurations, as well as novel delivery systems. These five patents further expand Bone Solutions’ industry footprint and allow surgeons and patients to further benefit from the advantages...

Bone Solutions Receives 510(k) Clearance for Expanded Indications of Use for Mg OSTEOCRETE in Intervertebral Body Fusion Procedures

COLLEYVILLE, Texas--(BUSINESS WIRE)--Bone Solutions Inc., an orthobiologics technology company located in Colleyville, Texas, announced today 510(k) clearance of Mg OSTEOCRETE from the U.S. Food and Drug Administration (FDA) for use in the intervertebral body disc space, including cervical, thoracic, and lumbar fusion procedures. This marks the first and only magnesium-based bone substitute to be cleared by the FDA for this application. This expanded indication allows surgeons and patients to f...
Back to Newsroom